Wednesday, March 29, 2023 | Back issues
Courthouse News Service Courthouse News Service

Shareholder Class Action

WILMINGTON, Del. - Pharmasset, which is developing a drug to treat hepatitis C, is selling itself too cheaply to Gilead Sciences, for $137 per share or $11 billion, shareholders say.

Read the Top 8

Sign up for the Top 8, a roundup of the day's top stories delivered directly to your inbox Monday through Friday.